|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.83/0.05
|
企业价值
166.56M
|
资产负债 |
每股账面净值
0.72
|
现金流量 |
现金流量率
--
|
损益表 |
收益
25.18M
|
每股收益
0.30
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/05 01:14 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine. |